Cytori Therapeutics Inc (CYTX) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.43 earnings per share for the quarter, missing the analyst consensus estimate by $-0.04. Analysts had a consensus of $-0.39. The company posted revenue of $1.10 million in the period, compared to analysts expectations of $3.00 million. The company’s revenue was down -31.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.
Cytori Therapeutics Inc closed down -0.04 points or -1.84% at $2.13 with 1,70,346 shares getting traded on Tusday. Post opening the session at $2.15, the shares hit an intraday low of $2.07 and an intraday high of $2.17 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jun 15, 2016, David Rickey (director) purchased 5,000 shares at $2.10 per share price. According to the SEC, on Jun 15, 2016, Gail K Naughton (director) purchased 1,000 shares at $2.10 per share price. On May 16, 2016, John David Harris (VP and GM Cell Therapy) purchased 2,000 shares at $2.71 per share price, according to the Form-4 filing with the securities and exchange commission.
Cytori Therapeutics Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product Cytori Cell Therapy for patients with scleroderma hand dysfunction orthopedic disorders cardiovascular disease urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe Japan and other regions. The Company offers ECCO-50 a cure for knee osteoarthritis which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50 a cure for urinary incontinence which is in Phase II/III of development. The Company is also developing DCCT-10 a cure for cutaneous thermal injury.